F-18 16 Alpha-Fluoroestradiol

Phase 2Small molecule

F-18 16 Alpha-Fluoroestradiol is one of 41 small molecule programs targeting HER2/Neu Negative. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Her2/neu NegativeActive, not recruiting

Estrogen Receptor PositiveActive, not recruiting

Breast CancerRecruiting

Her2/neu NegativePhase 2

Active, not recruiting

Estrogen Receptor PositivePhase 2

Active, not recruiting

Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

F-18 16 Alpha-Fluoroestradiol

UUniversity of Washington

Phase 2

3 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Breast Cancer

NCT06260033

Phase 2Active, not recruiting

Her2/neu Negative

NCT02398773

Q4 2028

Phase 2Recruiting

Breast Cancer

NCT07112053

Q2 2041

Phase 2Active, not recruiting

Estrogen Receptor Positive

NCT04692103

Clinical

Trials by Indication[1]

Breast Cancer3 trials

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Terminated·UUniversity of Washington·N/A·NCT02149173·29 enrolled

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Recruiting·—·Phase 2·NCT06260033·18 enrolled

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Recruiting·UUniversity of Washington·Phase 2·NCT07112053·40 enrolled

Desmoid Tumor1 trial

18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1·NCT02374931·3 enrolled

Estrogen Receptor Positive1 trial

Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-targeted Therapy

Active, not recruiting·UUniversity of Washington·Phase 2·NCT04692103·2 enrolled

HER2/Neu Negative1 trial

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02398773·99 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for F-18 16 Alpha-Fluoroestradiol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — F-18 16 Alpha-Fluoroestradiol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for F-18 16 Alpha-Fluoroestradiol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Washington company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Washington

F-18 16 Alpha-Fluoroestradiol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Q2 2041

Trials by Indication[1]

Breast Cancer3 trials

Desmoid Tumor1 trial

Estrogen Receptor Positive1 trial

HER2/Neu Negative1 trial

References

Drug Info

Quick Facts

Related News